{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"PROVIDENCE&#160;- Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (PROVIDENCE)","eudractNumber":null,"id":10995,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"}],"nctNumber":"NCT05573893","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-09-18T10:44:59+02:00","shortTitle":"Registerstudie PROVIDENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Digital Monitoring with Patient-reported outcomes in cancer care: A randomized controlled trial","eudractNumber":null,"id":11846,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06867705","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T13:00:46+01:00","shortTitle":"Resilience- RC-102","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Retentionsrate von Acalabrutinib in einem nicht-interventionellen Setting","eudractNumber":null,"id":9260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05645172","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-05T10:59:16+01:00","shortTitle":"Retain","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy (SAPHIR)<br />","eudractNumber":null,"id":5701,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04290806","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-12-19T08:58:50+01:00","shortTitle":"SAPHIR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p>Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing </p>","eudractNumber":null,"id":7907,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRCA (BReast CAncer)","id":"mt_204"}],"nctNumber":"NCT04830709","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-13T13:30:32+01:00","shortTitle":"SCOUT-1","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:50:42+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Systematische Erfassung und Einbeziehung von Patientinnen:pr&#228;ferenzen* in individuelle Entscheidungsfindung und aggregierte Leitlinienempfehlungen","eudractNumber":null,"id":11462,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-07-30T13:44:15+02:00","shortTitle":"SEP-SDM-LL","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Klinische Forschungsplattform zur Behandlung von Eierstock-, Eileiter-, prim&#228;rem Bauchfell- und Geb&#228;rmutterschleimhautkrebs und deren Folgen","eudractNumber":null,"id":7358,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05129969","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T09:06:49+01:00","shortTitle":"SMARAGD","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, retrospektives/prospektives, multizentrisches Register zu Erfassung der Behandlungspraxis von Patientinnen mit einem STIC (ser&#246;s tubares intraepitheliales Karzinom) oder einer STIL ( ser&#246;s tubare intraepitheliale L&#228;sion) in der klinischen Routine","eudractNumber":null,"id":11145,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-03-29T13:59:10+01:00","shortTitle":"STIC-Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Prospective Registry Study: Metastatic Soft Tissue Sarcoma<div>DRKS00035722<br /><div><br /></div></div>","eudractNumber":null,"id":11205,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-08-17T09:43:09+02:00","shortTitle":"STS-met","therapeutical":false,"therapyLines":[]}]}